IDH inhibition in AML therapy - 101793

Spotlight
Video

IDH inhibition in AML therapy

VJHemOnc has 922 videos Subscribe Here

Loading........
Description: The last 5-10 years has been a very exciting time for the treatment of myeloid malignancies, with great advances in targeted therapies. Amir Fathi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses therapy targeting isocitrate dehydrogenase (IDH) in acute myeloid leukaemia (AML). Dr Fathi highlights studies which hare evaluating IDH inhibitors as a monotherapy or in combination with other types of treatment, for which the preliminary data is promising. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 02/05/18
Added : 16 days ago



Recommended

Nothing found.

More From VJHemOnc

Nothing found.